NASDAQ NMS - GLOBAL MARKET · AMGN
-1.41% · -$5.23 · Vol 2.9M
Market closed · last close 4:00 PM ET · price as of 17:56:09 ET
Amgen Inc

Amgen Inc

Biotechnology
$366.35
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is AMGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for AMGN are being assembled.
About Amgen Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1983
Employees
32K
Country
US

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$373.97
Day high
$378.54
Day low
$361.72
Previous close
$371.58
52W high
$388.16
-5.62% from high
52W low
$271.18
81% of range
Market cap
$197.7B
P/E
24.23×
EPS
$15.12
Beta
0.42
Shares out
539.7M
Volume
2.9M
1.00× rel vol
Avg volume
2.9M
VWAP
$367.50
Price history computed in-house
1W
+1.64%
1M
+8.52%
3M
+6.23%
1Y
+24.29%
YTD
+11.93%
SMA 50 $346.50 · above
SMA 200 $339.65 · above
52W position 81%
Veridion warehouse edge

Warehouse intelligence for AMGN.

Veridion Score
49
Checking plan access.
Congress 30d
4
Ro Khanna · Purchase
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the AMGN research trail.

Relationship mapTrace receipt-backed holders and filings around AMGN.Congress disclosuresOpen receipt and filing context for AMGN.MethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

Receipt-backed filing rows for AMGN are being assembled from the latest scheduled snapshot.

Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

AMGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AMGN in this window.
Lobbying spend

AMGN lobbying filings, year to date.

Registered lobbying filings matched to Amgen Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AMGN in this window.
Latest news · AMGN
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for AMGN.
Options
Sovereign unlock shows live options positioning for AMGN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.